London, United Kingdom – A significant shift in how kidney function is assessed is offering renewed hope to thousands of Black patients awaiting life-saving transplants. For decades, a widely used formula, the estimated glomerular filtration rate (eGFR), systematically underestimated kidney health in Black individuals, leading to delayed evaluations and lower placement on the transplant list. Recent policy changes, spurred by growing awareness of this racial bias, are now actively working to correct these inequities, with early data showing promising results.
The eGFR test, designed to measure how well kidneys filter waste, is a crucial factor in determining transplant eligibility. Historically, the formula included a race-based variable that, while intended to improve accuracy, inadvertently disadvantaged Black patients. This variable inflated eGFR scores for Black individuals, effectively masking the severity of their kidney disease and delaying their access to potentially life-saving treatment. The issue stemmed from a flawed assumption that Black individuals generally have higher muscle mass, which was incorrectly factored into the calculation. This led to a systematic underestimation of kidney dysfunction in this population.
The impact of this bias was substantial. According to a March 2026 study highlighted by the Associated Press, over 21,000 Black kidney transplant candidates have received adjustments to their waitlist priority based on the revised calculations. These adjustments have resulted in a median increase of 1.7 years in their priority score, a significant improvement considering the average wait time for a kidney transplant ranges from three to five years, and can be considerably longer in certain regions. This correction acknowledges the time lost due to the previous, inaccurate assessments.
The History of Racial Bias in eGFR Calculations
The origins of the race-based eGFR formula date back to the 1990s, when researchers sought to refine the accuracy of kidney function assessment. While the intention was to improve diagnostic precision, the inclusion of race as a variable ultimately perpetuated systemic inequities. The formula’s reliance on race as a biological proxy, rather than acknowledging the social determinants of health that contribute to kidney disease disparities, proved to be deeply problematic. The practice continued for decades, despite growing concerns raised by medical professionals and advocates for health equity.
The turning point came with increasing scrutiny from nephrologists and researchers who began to question the scientific basis of the race-based variable. Studies revealed that the variable did not accurately reflect biological differences and, in fact, contributed to disparities in access to care. In 2021, the medical community began to acknowledge the inherent bias within the eGFR calculation. The Organ Procurement and Transplantation Network (OPTN), responsible for managing the national transplant system, initiated a review of the policy, ultimately leading to its revision in 2022. The HRSA provides FAQs for patients impacted by these changes.
Correcting the Imbalance: The OPTN’s Response
The OPTN, established in 1984 to improve the efficiency and equity of the organ transplant system, played a pivotal role in addressing the eGFR bias. Recognizing the harm caused by the previous formula, the OPTN implemented a policy to retroactively adjust the waitlist priority of Black kidney transplant candidates. This adjustment, based on the time lost due to the inaccurate eGFR scores, aims to level the playing field and ensure that Black patients receive timely access to transplantation.
Researchers at Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and Boston Medical Center rigorously evaluated the impact of this policy change. Their analysis, reported by the Associated Press, demonstrated that the adjustments were effective in improving the position of Black candidates on the transplant list. Dr. Rohan Khazanchi of Brigham and Women’s Hospital and Boston Medical Center, who led the study, stated that the policy “hopefully helps move the needle toward equity.” This sentiment reflects a broader commitment to addressing systemic racism within the healthcare system.
Disparities in Kidney Disease and Transplantation
The eGFR issue highlights the broader disparities that exist in kidney disease and transplantation. Black Americans are disproportionately affected by kidney failure, with rates significantly higher than those of White Americans. According to the Office of Minority Health, Black patients comprise roughly 30 percent of the kidney transplant waiting list, yet represent only about 13 percent of organ donors. The Office of Minority Health provides further information on organ transplants and African Americans. This disparity in donation rates further exacerbates the challenges faced by Black patients awaiting transplantation.
Several factors contribute to these disparities, including higher rates of hypertension and diabetes within the Black community, as well as limited access to quality healthcare and socioeconomic barriers. Addressing these underlying issues is crucial to achieving true equity in kidney care. Efforts to increase organ donation awareness and access within the Black community are also essential to bridging the gap between those in need and available organs.
Looking Ahead: Continued Efforts for Equity
While the recent changes to the eGFR calculation represent a significant step forward, the fight for equity in kidney transplantation is far from over. Ongoing monitoring and evaluation of the policy’s impact are crucial to ensure its effectiveness. Continued research is needed to identify and address the root causes of kidney disease disparities.
The medical community must remain vigilant in identifying and dismantling systemic biases that contribute to inequities in healthcare. This includes promoting diversity within the healthcare workforce, improving cultural competency among healthcare providers, and addressing the social determinants of health that disproportionately affect marginalized communities. The goal is to create a healthcare system that provides equitable access to care for all, regardless of race or ethnicity.
The OPTN continues to refine its policies and procedures to promote fairness and transparency in the organ transplant system. Future initiatives may include exploring alternative methods for assessing kidney function that do not rely on race, as well as expanding access to living donation opportunities. The ultimate aim is to ensure that all patients have a fair chance at receiving a life-saving kidney transplant.
The success of this policy change serves as a powerful reminder of the importance of challenging established practices and advocating for equitable healthcare policies. It demonstrates that when systemic biases are identified and addressed, meaningful progress can be made in improving the health and well-being of all communities.
The next step in this ongoing process will be a comprehensive review of the OPTN’s policy by an independent panel of experts in the spring of 2027, as announced by the organization in a recent statement. This review will assess the long-term impact of the changes and identify any areas for further improvement. Readers are encouraged to share their thoughts and experiences related to kidney transplantation and health equity in the comments below.
Related reading